156 related articles for article (PubMed ID: 36297384)
61. Phosphodiesterase 2A is a major negative regulator of iNOS expression in lipopolysaccharide-treated mouse alveolar macrophages.
Rentsendorj O; D'Alessio FR; Pearse DB
J Leukoc Biol; 2014 Nov; 96(5):907-15. PubMed ID: 25063878
[TBL] [Abstract][Full Text] [Related]
62. Discovery of Novel Phosphodiesterase-2A Inhibitors by Structure-Based Virtual Screening, Structural Optimization, and Bioassay.
Zhang C; Feng LJ; Huang Y; Wu D; Li Z; Zhou Q; Wu Y; Luo HB
J Chem Inf Model; 2017 Feb; 57(2):355-364. PubMed ID: 28055196
[TBL] [Abstract][Full Text] [Related]
63. TAK-915, a phosphodiesterase 2A inhibitor, ameliorates the cognitive impairment associated with aging in rodent models.
Nakashima M; Suzuki N; Shiraishi E; Iwashita H
Behav Brain Res; 2019 Dec; 376():112192. PubMed ID: 31521738
[TBL] [Abstract][Full Text] [Related]
64. Involvement of Phosphodiesterase 2A Activity in the Pathophysiology of Fragile X Syndrome.
Maurin T; Melancia F; Jarjat M; Castro L; Costa L; Delhaye S; Khayachi A; Castagnola S; Mota E; Di Giorgio A; Servadio M; Drozd M; Poupon G; Schiavi S; Sardone L; Azoulay S; Ciranna L; Martin S; Vincent P; Trezza V; Bardoni B
Cereb Cortex; 2019 Jul; 29(8):3241-3252. PubMed ID: 30137253
[TBL] [Abstract][Full Text] [Related]
65. Knockdown of lung phosphodiesterase 2A attenuates alveolar inflammation and protein leak in a two-hit mouse model of acute lung injury.
Rentsendorj O; Damarla M; Aggarwal NR; Choi JY; Johnston L; D'Alessio FR; Crow MT; Pearse DB
Am J Physiol Lung Cell Mol Physiol; 2011 Aug; 301(2):L161-70. PubMed ID: 21571906
[TBL] [Abstract][Full Text] [Related]
66. Binding of cyclic nucleotides to phosphodiesterase 10A and 11A GAF domains does not stimulate catalytic activity.
Matthiesen K; Nielsen J
Biochem J; 2009 Oct; 423(3):401-9. PubMed ID: 19689430
[TBL] [Abstract][Full Text] [Related]
67. A novel PDE2A reporter cell line: characterization of the cellular activity of PDE inhibitors.
Wunder F; Gnoth MJ; Geerts A; Barufe D
Mol Pharm; 2009; 6(1):326-36. PubMed ID: 19049345
[TBL] [Abstract][Full Text] [Related]
68. In vitro phosphodiesterase 10A (PDE10A) binding in whole hemisphere human brain using the PET radioligand [
Svedberg MM; Varnäs K; Varrone A; Mitsios N; Mulder J; Gulyás B; Beaumont V; Munoz-Sanjuan I; Zaleska MM; Schmidt CJ; Halldin C; Mrzljak L
Brain Res; 2019 May; 1711():140-145. PubMed ID: 30664847
[TBL] [Abstract][Full Text] [Related]
69. Preclinical and clinical study on [
Xu M; Guo J; Gu J; Zhang L; Liu Z; Ding L; Fu H; Ma Y; Liang S; Wang H
Eur J Nucl Med Mol Imaging; 2022 Jan; 49(2):652-663. PubMed ID: 34292345
[TBL] [Abstract][Full Text] [Related]
70. In vitro autoradiography and in vivo evaluation in cynomolgus monkey of [18F]FE-PE2I, a new dopamine transporter PET radioligand.
Varrone A; Steiger C; Schou M; Takano A; Finnema SJ; Guilloteau D; Gulyás B; Halldin C
Synapse; 2009 Oct; 63(10):871-80. PubMed ID: 19562698
[TBL] [Abstract][Full Text] [Related]
71. Specific binding of [(18)F]fluoroethyl-harmol to monoamine oxidase A in rat brain cryostat sections, and compartmental analysis of binding in living brain.
Maschauer S; Haller A; Riss PJ; Kuwert T; Prante O; Cumming P
J Neurochem; 2015 Dec; 135(5):908-17. PubMed ID: 26386360
[TBL] [Abstract][Full Text] [Related]
72. A ¹⁸F-labeled fluorobutyl-substituted spirocyclic piperidine derivative as a selective radioligand for PET Imaging of sigma₁ receptors.
Maisonial A; Grosse Maestrup E; Fischer S; Hiller A; Scheunemann M; Wiese C; Schepmann D; Steinbach J; Deuther-Conrad W; Wünsch B; Brust P
ChemMedChem; 2011 Aug; 6(8):1401-10. PubMed ID: 21618432
[TBL] [Abstract][Full Text] [Related]
73. Phosphodiesterase 2A localized in the spinal cord contributes to inflammatory pain processing.
Kallenborn-Gerhardt W; Lu R; Bothe A; Thomas D; Schlaudraff J; Lorenz JE; Lippold N; Real CI; Ferreirós N; Geisslinger G; Del Turco D; Schmidtko A
Anesthesiology; 2014 Aug; 121(2):372-82. PubMed ID: 24758774
[TBL] [Abstract][Full Text] [Related]
74. Low Expression of Phosphodiesterase 2 (PDE2A) Promotes the Progression by Regulating Mitochondrial Morphology and ATP Content and Predicts Poor Prognosis in Hepatocellular Carcinoma.
Chen L; Zhou J; Zhao Z; Zhu Y; Xing J; An J; Guo X
Cells; 2022 Dec; 12(1):. PubMed ID: 36611861
[TBL] [Abstract][Full Text] [Related]
75. N-(6-18F-fluorohexyl)-N-methylpropargylamine: a fluorine-18-labeled monoamine oxidase B inhibitor for potential use in PET studies.
Mukherjee J; Yang ZY; Lew R
Nucl Med Biol; 1999 Jan; 26(1):111-6. PubMed ID: 10096510
[TBL] [Abstract][Full Text] [Related]
76. Radiosynthesis and Preclinical Evaluation of an α
Krzyczmonik A; Keller T; López-Picón FR; Forsback S; Kirjavainen AK; Takkinen JS; Wasilewska A; Scheinin M; Haaparanta-Solin M; Sączewski F; Solin O
Mol Imaging Biol; 2019 Oct; 21(5):879-887. PubMed ID: 30710261
[TBL] [Abstract][Full Text] [Related]
77. [18F]F15599, a novel 5-HT1A receptor agonist, as a radioligand for PET neuroimaging.
Lemoine L; Verdurand M; Vacher B; Blanc E; Le Bars D; Newman-Tancredi A; Zimmer L
Eur J Nucl Med Mol Imaging; 2010 Mar; 37(3):594-605. PubMed ID: 19789870
[TBL] [Abstract][Full Text] [Related]
78. Pharmacological characterization of a novel potent, selective, and orally active phosphodiesterase 2A inhibitor, PDM-631.
Maehara S; Arakawa K; Hoshida K; Nagasue H; Chida N; Nakao K; Furusako S
Eur J Pharmacol; 2017 Sep; 811():110-116. PubMed ID: 28587776
[TBL] [Abstract][Full Text] [Related]
79. Synthesis, characterization, and monkey positron emission tomography (PET) studies of [18F]Y1-973, a PET tracer for the neuropeptide Y Y1 receptor.
Hostetler ED; Sanabria-Bohórquez S; Fan H; Zeng Z; Gantert L; Williams M; Miller P; O'Malley S; Kameda M; Ando M; Sato N; Ozaki S; Tokita S; Ohta H; Williams D; Sur C; Cook JJ; Burns HD; Hargreaves R
Neuroimage; 2011 Feb; 54(4):2635-42. PubMed ID: 21078401
[TBL] [Abstract][Full Text] [Related]
80.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
